Gauging the Antiobesity Potential of Oral Semaglutide in Type 2 Diabetes in the Indian Context
Keywords:
Obesity, oral GLP-1RA, semaglutide, weight lossAbstract
“Diabesity”, which combines type 2 diabetes (T2D) and obesity has emerged as a global epidemic in the modern world. Indeed, diabesity contributes significantly to increased morbidity, and the prevalence of this global health burden has steadily increased in India over the past three decades. Importantly, only a few pharmacological agents are currently available across the world, and India in particular has access to only a limited number of such agents. However, with the advent of oral glucagon-like peptide-1 receptor agonist (GLP-1RA) after its launch in India recently as an antidiabetic agent, the horizon to combat diabesity has expanded. With the available evidence from several phase 3 trials of oral GLP-1RA (PIONEER, Peptide Innovation for Early Diabetes Treatment), it is increasingly becoming apparent that oral semaglutide could have some potential to fulfil the US Food and Drug Administration criterion of an antiobesity agent.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
